Find a Clinical Trial

Showing 71 - 80 of 175 Trials

  • Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma

    Principal Investigator:

    Kazuki Sugahara, MD, PHD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03127774

    Population:

    Adult

    Phase:

    II
    motherapy can improve survival in patients with metastatic adrenal cortical carcinoma. Are you Eligible? (Inclusion Criteria) * Histologically proven ACC with the majority of disease confined to the peritoneal cavity and resectable; or disease that in the opinion of the investigators can be managed medically or surgically and does not present an immediate threat to the patient’s life. * Disease evaluable by CT or PET imaging * All disease should be deemed resectable based on imaging studies e.g.: - Hepatic metastases (unilateral or bilateral ≤5 lesions, ≤...

  • Phase II, Neoadjuvant study of parasympathetic stimulation with bethanechol in combination with gemcitabine and nab-paclitaxel in borderline resectable pancreatic adenocarcinoma

    Principal Investigator:

    Susan E. Bates, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05241249

    Population:

    Adult

    Phase:

    II
    of this study is to determine whether the drug, bethanechol, could potentially be used in combination with chemotherapy regimen gemcitabine and nab-paclitaxel and surgery to decrease the chance of the cancer coming back after it is removed. Animal models have shown that treatment with bethanechol can inhibit cancer growth and spread. The chemotherapy regimen nab-paclitaxel for use in combination with gemcitabine to treat patients with metastatic pancreatic cancer is FDA approved. Although bethanechol is FDA approved, in this study its use is experimental. The aim of the study is to show that...

  • Phase II study of Polatuzumab vedotin in combination with chemotherapy in subjects with Richter's Transformation

    Principal Investigator:

    Andrew H Lipsky, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04679012

    Population:

    Adult

    Phase:

    II
    This research is being done because Richter’s transformation, which is a life- threatening complication of chronic lymphocytic lymphoma (CLL), and is associated with poor overall survival rate. The study drug administration is a combination of the investigational drug, Polatuzumab vedotin, in combination with Rituximab, Etoposide, Prednisone, Cyclophosphamide, and Hydroxydaunorubicin, also referred to as PolaR-EPCH. An investigational drug means it has not been approved by the FDA or any other international regulatory agencies. The purpose of this study is to find out what effects the...

  • Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04726241

    Population:

    Pediatrics/Adult

    Phase:

    II
    This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other information about leukemia that is important when deciding how to best treat leukemia. Are you Eligible? (Inclusion Criteria) Patients must be 21 years of age or younger Patient must have one of the following: A. Patient has known or suspected relapsed/refractory (including...

  • Pembrolizumab in combination with gemcitabine for previously treated mycosis fungoides and Sezary syndrome: efficacy and characterization of immune response

    Principal Investigator:

    Larisa J Geskin, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04960618

    Population:

    Adult

    Phase:

    II
    Primary objective: Determine preliminary clinical effectiveness of pembrolizumab plus gemcitabine in previously treated MF and SS with overall response rate (ORR) using the composite global response criteria including: radiological imaging (PET/CT scans), flow cytometry and mSWAT assessments. 2. Secondary objectives: a. To estimate duration of response (DOR) of pembrolizumab plus gemcitabine in previously treated MF and SS. b. To estimate progression-free survival (PFS) pembrolizumab plus gemcitabine in previously treated MF and SS. c. To estimate overall survival (OS) of patients with...

  • Phase II single arm study testing SBRT, Adenosine signaling Modulation (AB680, AB928), and Immune Checkpoint inhibition (AB122) for men with hormone sensitive Oligometastatic prostate cancer (SBRT-AMICO)

    Principal Investigator:

    Catherine S Spina, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05915442

    Population:

    Adult

    Phase:

    II
    This study aims to test the safety and effectiveness of zimberelimab, etrumadenant, and quemliclustat when given together with radiotherapy as a potential treatment to hormone sensitive oligometastatic (cancer that has spread to other areas of the body) prostate cancer. Zimberelimab, etrumadenant, and quemliclustat are considered immunotherapy drugs. These type of drug works by blocking a protein that can cause tumors to grow. By blocking this protein, the study drugs may cause your cancer to stop growing or to shrink. These study drugs are not approved by Health Authorities including the...

  • Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder: HCRN GU22-598

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06809140

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to see if the combination of enfortumab vedotin and pembrolizumab leads to no detectable cancer on early assessments of the bladder after initial treatment. We are asking you to take part in this research study because you have muscle-invasive bladder cancer. This combination of enfortumab vedotin and pembrolizumab has been tested in people and is approved by the U.S. Food and Drug Administration (FDA) to treat patients with bladder cancer that has spread outside of the bladder (also known as metastatic bladder cancer).Enfortumab vedotin and Pembrolizumab are not...

  • Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05890352

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large b-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of tazemetostat or zanubrutinib to the usual treatment could shrink the cancer or extend your time without cancer symptoms coming back. But it may also cause side effects, which the doctors will monitor. This study will help the study doctors find out...

  • Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma

    Principal Investigator:

    Mary R. Welch, MD, MS

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06325683

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to compare the usual treatment to using the study drugs, relatlimab and nivolumab in patients with recurrent brain cancer. The use of the study drugs, relatlimab and nivolumab, could shrink or stabilize your cancer. But, they could also cause side effects, which the study team will be monitoring. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drugs increase the life of patients compared to the usual...

  • Randomized double blind phase 2 trial of baby exemestaneversus baby tamoxifen in post-menopausal women at highrisk for breast cancer.BabyTEARS (Baby Tamoxifen or Exemestane AssessmentRandomized Study)

    Principal Investigator:

    Katherine D Crew, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06364267

    Population:

    Adult

    Phase:

    II
    This study wants to find out if a low dose of BabytamTamoxifen (called Babytam) works better than a low dose of Babyexe Exemestane (called Babyexe) in helping with physical problems like joint pain. We will check this using a special questionnaire about menopause symptoms after 12 months of treatment. This questionnaire is a trusted way to see how menopause or low estrogen affects women, and how these medicines might change those symptoms. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of the investigational drugs, to learn whether...

Pages